Inflammatory bowel disease approaching the 3rd millennium: pathogenesis and therapeutic implications?

被引:21
作者
Ardizzone, S [1 ]
Bollani, S [1 ]
Manzionna, G [1 ]
Porro, GB [1 ]
机构
[1] Univ Hosp, Gastrointestinal Unit L Sacco, Milan, Italy
关键词
Crohn's disease; inflammatory bowel disease; ulcerative colitis;
D O I
10.1097/00042737-199901000-00006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The aetiology of inflammatory bower disease remains unknown, but genetic, immuno-inflammatory, infectious, vascular and neural factors play an important role. All effective treatments in use today were introduced empirically and most have multiple action. Targeted therapy is very attractive, either with cell and gene therapy or by using specific cytokine inhibitors and inhibitory cytokines. The role of the intestinal milieu, and enteric flora in particular, appears to have a much greater significance than previously appreciated. The reduction of any changes leading to pro-coagulant activity may be a promising line of therapeutic investigation, and measures to reduce platelet aggregation and endothelial cell adhesiveness are examples of therapeutic potentials. Finally, there has been tangible demonstration of the ability of nerves to alter the inflammatory process which will lead to new therapeutic approaches in inflammatory bower disease. Eur J Gastroenterol Hepatol 11:27-32 (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 49 条
[1]  
ARDIZZONE S, IN PRESS GUT
[2]  
Arlander E, 1996, ALIMENT PHARM THERAP, V10, P73
[3]   Molecular medicine - Antisense oligonucleotide therapy [J].
Askari, FK ;
McDonnell, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :316-318
[4]  
BJORCK S, 1992, AGENTS ACTIONS, pC60
[5]   Therapeutic potential for blockade of the CD40 ligand, gp39 [J].
Buhlmann, JE ;
Noelle, RJ .
JOURNAL OF CLINICAL IMMUNOLOGY, 1996, 16 (02) :83-89
[6]   Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody [J].
CanvaDelcambre, V ;
Jacquot, S ;
Robinet, E ;
Lemann, M ;
Drouet, C ;
Labalette, M ;
Dessaint, JP ;
Bengoufa, D ;
Rabian, C ;
Modigliani, R ;
Wijdenes, J ;
Revillard, JP ;
Colombel, JF .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (05) :721-727
[7]   The immunomodulation of enteric neuromuscular function: Implications for motility and inflammatory disorders [J].
Collins, SM .
GASTROENTEROLOGY, 1996, 111 (06) :1683-1699
[8]  
COMINELLI F, 1994, J BIOL CHEM, V269, P6962
[9]   RECOMBINANT INTERLEUKIN-1 RECEPTOR ANTAGONIST BLOCKS THE PROINFLAMMATORY ACTIVITY OF ENDOGENEOUS INTERLEUKIN-1 IN RABBIT IMMUNE COLITIS [J].
COMINELLI, F ;
NAST, CC ;
DUCHINI, A ;
LEE, M .
GASTROENTEROLOGY, 1992, 103 (01) :65-71
[10]  
DEUSCH K, 1993, GASTROENTEROLOGY, V104, pA691